Major histocompatibility complex (MHC) class II deficiency is a rare form of primary combined immunodeficiency that can only be corrected by stem cell transplantation. We report a 4.-year-old girl with MHC class II deficiency who underwent a related CBT due to graft failure following T cell-depleted non-identical BMT. The patient is alive and well 2 years after the second transplant. A sustained hematopoietic engraftment and a progressive immune recovery have been detected. We conclude that cord blood may be an effective source of hematopoietic stem cells for patients with immunodeficiency disorders including diseases with a high rate of graft failure. Keywords: SCID; cord blood transplantation; T celldepleted BMT Major histocompatibility complex (MHC) class II deficiency is a rare form of primary combined immunodeficiency syndrome characterized by defective expression of HLA class II antigens, inconsistent and incomplete expression of HLA class I molecules, and lack of cellular and humoral immune response to foreign antigens.
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Case report
In May 1994, a girl was born at term by caesarean section after an uncomplicated pregnancy. During the neonatal period she received BCG immunization without any local or systemic responses. Four brothers, two of them twins, died before the age of 2 years of recurrent pneumonia. Her maternal aunt had died from coqueluche in her childhood. Although the parents are from a small village they are unaware that they may be related. At 4 months she had thrush that disappeared with nistatin. At 7 months she presented with failure to thrive, bilateral otitis and urinary tract infection. She was subsequently hospitalized three times for diarrhea, otitis and dehydration.
In June 1995, at the age of 13 months, she was admitted to our institution because of failure to thrive, chronic diarrhea and persistent thrush. The diagnosis of MHC class II deficiency was based on the family and personal history of recurrent severe infections, and was confirmed by the absence of DR antigen expression on monocytes and B lymphocytes with normal expression of HLA class I antigens. Red blood cell concentrations of adenosine deaminase and purine nucleoside phosphorylase were normal. The immunologic results are shown in Table 1 . Intravenous immune globulin (IVIG) and prophylactic trimethoprimsulfamethoxazole were begun after this diagnosis.
In March 1996, no identical family donor was found and a two-antigen mismatched BMT from the father was performed. Conditioning consisted of busulfan (5 mg/kg/day from day Ϫ9 to day Ϫ6), cyclophosphamide (50 mg/kg/day from day Ϫ5 to day Ϫ2); moreover, monoclonal anti-LFA1 antibody (0.2 mg/kg/day from day Ϫ3 to ϩ10) and monoclonal anti-CD2 antibody (0.2 mg/kg/day from day Ϫ2 to ϩ11) were employed to prevent graft rejection. The graft was T cell depleted by means of soybean agglutination and E-rosetting; the patient received 0.2 ϫ 10 8 per kg mononuclear cells and 1.6 ϫ 10 5 per kg T cells. She was placed in an isolation room with laminar airflow. Supportive care included total parenteral nutrition, gut decontamination, prophylactic acyclovir and weekly IVIG administration. Cyclosporine was administered as GVHD prophylaxis until day 60. Fever and diarrhea appeared on day ϩ9 and broadspectrum antibiotics were given. Grade II graft-versus-host disease of the skin (confirmed histologically) developed on day ϩ20 and resolved after treatment with methylprednisolone. The neutrophil count was Ͼ0.5 ϫ 10 9 /l on day ϩ10, Ͼ1.0 ϫ 10 9 /l on day ϩ12 and platelets Ͼ50 ϫ 10 9 /l without transfusion support on day ϩ62. No signs of chronic graft-versus-host disease were observed. The immunologic values after BMT are shown in Table 1 . One year post BMT a very low DR expression on monocytes and B cells was found. The graft failure was also documented by lymphocytic karyotype and fluorescence in situ hybridization (FISH) evaluation of sex chromosome chimerism on bone marrow, which showed 98% of the cells were of the recipient origin. Due to the aforementioned results a second transplant was planned.
The patient's mother became pregnant in July 1996. A fetal blood sample revealed a male fetus without evidence of immunodeficiency disorder. In January 1997, the baby was delivered by caesarean section with no complications and 75 ml of cord blood were collected and cryopreserved unmodified in DMSO 20%. After his birth a second immunologic evaluation showed normal values for his age and the tissue typing (HLA-A,B, DR) confirmed that the boy was HLA-identical to his sister. HLA-class II molecular typing was performed by polymerase chain sequencespecific primer technique. The ABO blood group was O in both of them. In March 1997 at the age of 34 months, after the patient's parents gave written informed consent, the girl underwent a second transplant with her brother's cord blood. Cyclophosphamide (60 mg/kg on days Ϫ5 and Ϫ4), total body irradiation (12 Gy total dose given in 6 fractions over 3 days) and horse antilymphocyte globulin (PasteurMérieux, Lyon, France, 30 mg/kg on days Ϫ2, Ϫ1 and ϩ1) were used as conditioning. The CB unit was thawed and infused following the procedure described by Rubinstein et al. 6 She received 6 ϫ 10 7 /kg mononuclear cells and 0.5 ϫ 10 6 /kg CD34 ϩ cells. Granulocyte colony-stimulating factor (5 g/kg day) was given from day ϩ1 to day ϩ60. On day ϩ4 she had fever, conjunctivitis, a lesion on the helix and neutropenia. She received broad-spectrum antibiotics. Initial cultures were negative. On day ϩ35 she became febrile again without signs of engraftment; imipenem, amikacin and amphotericin were given. She remained febrile and on day ϩ59 a positive blood culture for Candida parapsilosis was reported. Liposomal amphotericin was begun up to a total dose of 30 mg/kg. On day ϩ64 she had hepatomegaly and an echography disclosed a large pericardial effusion; a surgical drainage was performed. Pericardial fluid and biopsy cultures were negative. The fever subsided and no cardiologic complications were observed. The neutrophil count was Ͼ0.5 ϫ 10 9 /l on day ϩ48, Ͼ1.0 ϫ 10 9 /l on day ϩ52 and platelet count Ͼ50.0 ϫ 10 9 /l without transfusion support on day ϩ120. Limited chronic graft-versus-host disease was diagnosed by skin biopsy on day ϩ125 with good response to steroids.
Lymphocytic karyotype and FISH on bone marrow showed 95% male cells on day 30; complete chimerism was found on peripheral blood cells at various times after transplantation. Donor cells were also identified in the patient's peripheral blood as determined by HLA-DR typing ( Table 1 ). The pattern of immunological recovery is shown in Table 1 . A progressive increase of B cells from the third to the sixth months without an increase of serum immunoglobulins was found. No changes in the physical examination and no spontaneous outgrowth of transformed B lymphocytes ex vivo were found; moreover, Epstein-Barr virus (EBV) DNA and RNA by PCR methods were not detected. Treatment with IVIG was discontinued 12 months after the second transplant. Four and 10 months later, antibody production in response to tetanus toxoid immunization is partially positive whereas no response to pneumococcal vaccine has been detected. At the age of 4. years (2 years after CBT) the girl is clinically well without signs of chronic GVHD and free of infections.
Discussion
Major histocompatibility complex class II deficiency is a rare inborn error of the immune system characterized by impaired antigen presentation and combined immunodeficiency. 5 The natural history of MHC class II deficiency is dismal, with patients dying at a mean age of 4 years, often of overwhelming viral infections. 3, 5 This is an autosomal recessive disease caused by impaired gene regulation involving trans-acting proteins. 7 This group of disorders is rapidly fatal without allogeneic bone marrow transplantation. 4, 5 A favorable outcome was associated with an age of less than 2 years, before the acquisition of chronic virus carriage and sequelae of infections. 5 In the absence of an HLA-identical donor, T cell-depleted haploidentical BMT is the most developed treatment option. 5 The main cause of treatment failure in HLA-non-identical BMT is graft failure. In contrast to other forms of SCID, MHC class II deficient patients develop a normal T cell repertoire, and they show inducible alloreactive T lymphocytes that can initiate immunologic rejection or hamper engraftment. 5 In some studies, the use of anti-LFA 1 and anti-CD2 coincided with the development of full chimerism, without graft rejection, in successfully transplanted children with HLA class II deficiency and other immunodeficiencies. 5 On the basis of the previous data these two monoclonal antibodies in combination with the standard conditioning regimen were used on our patient in the first transplant. Due to the fact that only a partial and transient immune recovery was detected a second transplant with a related CB from a healthy brother was performed. For the aforementioned reasons an intensive conditioning regimen, including radiotherapy, was used on this occasion.
The use of either related or unrelated donor umbilical cord blood is becoming an alternative source of hematopoietic stem cells for allogeneic transplantation in a variety of malignant and non-malignant diseases. 8, 9 Scarce data about the immune reconstitution post CBT have been reported. Immune recovery is notable for increased B and NK cell populations. T cell recovery is marked by early emergence of CD4 ϩ T cells with a mature T cell receptor repertoire but diminished cytokine production. In vitro proliferative reponses to PHA and tetanus toxoid were reduced at day ϩ100.
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The recovery of T cell immunity in our patient showed the appearance of CD3 ϩ T cells with a marked predominance of CD4 ϩ T cells that persisted for 12 months post CBT when an inverted CD4:CD8 ratio was observed. Although a progressive increase of CD3 ϩ , CD4 ϩ and CD8 ϩ T cell counts has been detected up to the present (2 years post CBT), they are still below the normal values for her age except for CD8 counts that reached normal levels keeping a persistent inversion of the CD4:CD8 ratio. T cell proliferation to mitogens and allogeneic cells (data not shown) have so far achieved a good response whereas no response to the specific antigens tested was found. Normal numbers and activity of natural killer cells have been found. The transient B cell increase was not related to an EBV-associated lymphoproliferative disorder. Although a normal number of B cells, titers of isohemagglutinins and serum immunoglobulins were achieved, the humoral immunity is still impaired, which is shown by the patient's inability to mount a specific antibody production in response to polysaccharide vaccine. The development of full T and B cell functions may be related to the fact that it was a second transplant. This report affirms the potential for transplantation of cord blood stem cells to achieve sustained hematopoietic and lymphopoietic engraftment in patients with combined immunodeficiencies including diseases with a high rate of graft failure.
